Skip to main content
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its

Dr. John Cush RheumNow

1 year 10 months ago
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop

sheila RHEUMarampa

1 year 10 months ago
A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl
2023 @ACRheum guidance recommends #MediterraneanDiet in RA

What are barriers/facilitators to following the diet?

Many

Mrinalini Dey DrMiniDey

1 year 10 months ago
2023 @ACRheum guidance recommends #MediterraneanDiet in RA What are barriers/facilitators to following the diet? Many pts are willing to try but don't follow it Barriers➡️ food insecurity & aversions Many are unaware Do you talk to your pts about diet? Ab1673 #ACR24 @RheumNow
Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC

Richard Conway RichardPAConway

1 year 10 months ago

Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT https://t.co/dShyBF4WST

RA-ILD:
💡Lifetime prevalence seems low but ~40% can have subclincal.
💡Screen early in symptomatic pts.
💡RA dise

Adela Castro AdelaCastro222

1 year 10 months ago
RA-ILD: 💡Lifetime prevalence seems low but ~40% can have subclincal. 💡Screen early in symptomatic pts. 💡RA disease control decreases ILD progression and mortality. 💡RA-ILD UIP pattern seems to respond to immunosuppression. #ACR24 @RheumNow https://t.co/q3iACMeYVU
When you stop 🛑 #TCZ #tocilizumab at
6 months of #Rx in #PMR
RELAPSES are V high

DON’T stop #Toci in PMR too
Earl

Janet Pope Janetbirdope

1 year 10 months ago
When you stop 🛑 #TCZ #tocilizumab at 6 months of #Rx in #PMR RELAPSES are V high DON’T stop #Toci in PMR too Early Rapid and frequent flares #ACR24 @RheumNow @ACRheum #1698 https://t.co/IX5EJOcIY5
A#1692
Single cell RNA-seq identifies double-negative-2 (DN2) B-cell population ass w progressive SSc-ILD
IgD- CD27- clu

Eric Dein ericdeinmd

1 year 10 months ago
A#1692 Single cell RNA-seq identifies double-negative-2 (DN2) B-cell population ass w progressive SSc-ILD IgD- CD27- cluster is highest risk CD21 low B cells are distinct subset associated with sclerosis, pHTN DN2 B cells as potential biomarkers for SSc-ILD @RheumNow #ACR24 https://t.co/IbnOGS8C3t
Subgroup data from SELECT GCA, overall reinforces overall message

I was curious to see pts previously treated with TCZ;

Mike Putman EBRheum

1 year 10 months ago
Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3
This will change my practice!
#RCT #MMF + #MTX
superior to
#Cyclophosphamide then #Azathioprine

In
#Tayakasu’s #ar

Janet Pope Janetbirdope

1 year 10 months ago
This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx
Which subsets of GCA pt might benefit most from upadacitinib?

Sub-analysis from SELECT-GCA presented today:
💥Both re

Brian Jaros, MD Dr_Brian_MD

1 year 10 months ago
Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR
A#1690 fibroblast activation protein inhibitor (FAPI)-PET in SSc ILD

Introduces FAPI quantification algorithm

FAPI upt

Eric Dein ericdeinmd

1 year 10 months ago
A#1690 fibroblast activation protein inhibitor (FAPI)-PET in SSc ILD Introduces FAPI quantification algorithm FAPI uptake predicts greater rate of FVC decline. Trend for DLCO, not statistically signif FAPI volume & intensity both predict accel lung decline #ACR24 @RheumNow https://t.co/YA2ptLDaMy
Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF

Richard Conway RichardPAConway

1 year 10 months ago
Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj
Safer and less relapses in
#Takayasu’s #arteritis
In
#MTX + #MMF
Vs
#Cyclo ➡️ #azathioprine

@RheumNow #ACRBes

Janet Pope Janetbirdope

1 year 10 months ago
Safer and less relapses in #Takayasu’s #arteritis In #MTX + #MMF Vs #Cyclo ➡️ #azathioprine @RheumNow #ACRBest @ACRheum abst#1696 WOW 😮 Amazing! https://t.co/y3BDjdAa6P
×